Literature DB >> 25623674

Ureterorenoscopy for upper tract urothelial carcinoma: how often are we missing lesions?

Tammer Yamany1, Jason van Batavia2, Jennifer Ahn2, Edan Shapiro2, Mantu Gupta2.   

Abstract

OBJECTIVE: To determine the ability of ureterorenoscopy (URS) to identify the precise number and location of all lesions as compared with pathologic review of nephroureterectomy specimens, which have not been previously determined. Upper tract urothelial carcinoma (UTUC) comprises 5% of all urothelial malignancies in the United States. With advances in endoscopic equipment, there has been a move toward using flexible ureteroscopes to perform URS as part of the diagnostic evaluation and management.
METHODS: We identified patients who had undergone URS with biopsy before radical nephroureterectomy for UTUC. Operative reports for each procedure were reviewed and compared with the surgical pathology reports.
RESULTS: URS correctly identified the number and location of lesions in 57 of 76 patients (75%). The most common locations for missed lesions were in the ureter (9 patients) and renal pelvis (8 patients). Carcinoma in situ was missed on the initial biopsy for 9 patients. Three of 11 patients (27%) with a solitary lesion in the distal ureter visualized by URS had a missed lesion in the renal pelvis. URS with biopsy accurately predicted the grade of UTUC lesions in 79% of cases, whereas 65% of patients were upstaged on final pathology.
CONCLUSION: URS with biopsy can accurately map UTUC in the majority of patients. However, up to 25% of patients will have missed lesions, and nearly 50% of these patients will have a missed carcinoma in situ lesion. Undergrading and understaging of UTUC lesions remain shortcomings with potentially severe consequences.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 25623674     DOI: 10.1016/j.urology.2014.08.030

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  8 in total

Review 1.  Endoscopic Treatment of Upper Tract Urothelial Carcinoma.

Authors:  Daniel P Verges; Costas D Lallas; Scott G Hubosky; Demetrius H Bagley
Journal:  Curr Urol Rep       Date:  2017-04       Impact factor: 3.092

2.  Nephron sparing endoscopic treatment for primary carcinoma of the renal calyx: A case report and literature review.

Authors:  Q I Wang; Tong-Wen Ou; Jia-Wei Xu; Jin Li; Ali Borazjani; Chun-Song Jia; X U Wang; Hao Yan
Journal:  Mol Clin Oncol       Date:  2016-04-20

3.  Ex-vivo Imaging of Upper Tract Urothelial Carcinoma Using Novel pH Low Insertion Peptide (Variant 3), a Molecular Imaging Probe.

Authors:  Joseph Brito; Borivoj Golijanin; Ohad Kott; Anna Moshnikova; Catrina Mueller-Leonhard; Boris Gershman; Oleg A Andreev; Yana K Reshetnyak; Ali Amin; Dragan Golijanin
Journal:  Urology       Date:  2019-01-16       Impact factor: 2.649

Review 4.  Are we closer to seeing carcinoma in situ in the upper urinary tract?

Authors:  Sławomir G Kata; Omar Aboumarzouk
Journal:  Cent European J Urol       Date:  2016-04-26

Review 5.  Outcomes of endoscopic management of upper tract urothelial carcinoma.

Authors:  John J Knoedler
Journal:  Transl Androl Urol       Date:  2020-08

6.  Ex Vivo Near-Infrared Molecular Imaging of Human Upper Urinary Tract Urothelial Carcinoma With a CD47-Based Targeted Tracer.

Authors:  Pengyu Yan; Dan Chen; Xutao Yan; Xiaoting Yan; Yingpeng Wang; Chao Liu; Xiaofeng Yang
Journal:  Front Oncol       Date:  2022-02-28       Impact factor: 6.244

Review 7.  Current status of flexible ureteroscopy in urology.

Authors:  Sung Yong Cho
Journal:  Korean J Urol       Date:  2015-10-13

8.  Treatment of upper tract urothelial carcinoma with ureteroscopy and thulium laser: a retrospective single center study.

Authors:  Jin Wen; Zhi G Ji; Han Z Li
Journal:  BMC Cancer       Date:  2018-02-17       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.